Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer

Patients with unresectable pancreatic cancer are often demoralized by intractable, persistent and incapacitating pain. It must be managed aggressively and strong opioids are recommended as the mainstay of treatment. However, patients develop opioid-related adverse effects. EUS-guided celiac plexus neurolysis (CPN) and celiac ganglion neurolysis (CGN) has been shown to provide high efficacy for pain control. The optimal timing, however, is in debate.

Trial Details

NCT ID
NCT06160323
Phase
NA
Sponsor
Chinese University of Hong Kong
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis
Locations (sample)
  • Hong Kong, Hong Kong, Hong Kong|22.27832,114.17469

Key Eligibility Criteria

  • Age \>= 18 years old
  • Diagnosed to have inoperable pancreatic cancer
  • Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS \>= 3
  • Karnofsky performance status \>= 60

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →